Skip to main content

Advertisement

Log in

Autoimmune hemolytic anemia in patients with relapsed Hodgkin’s lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1

  • Short Report
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

In August 2021, penpulimab, an anti-programmed cell death 1 (PD-1) monoclonal antibody, was approved in China for the treatment of adult patients with relapsed or refractory classic Hodgkin’s lymphoma who completed at least second-line chemotherapy. Penpulimab is currently in clinical trials in China and Australia for the treatment of nasopharyngeal cancer and non-small cell lung cancer. Several clinical studies have shown that penpulimab is safe and effective, and no immune-related adverse events (irAEs) above grade 3 were observed. A 60-year-old woman with relapsed Hodgkin’s lymphoma developed nausea and fatigue after receiving penpulimab monotherapy (200 mg every 2 weeks). Ten days after the second injection, the patient’s condition worsened, and biochemical test results confirmed autoimmune hemolytic anemia (AIHA), with a hemoglobin level of 70 g/L (normal range, 115–150 g/L), an unconjugated bilirubin level of 19.08 µmol/L (normal range, 0–17 µmol/L), and positive direct antiglobulin test (DAT) results. On the same day, we treated her with prednisone (2 mg/kg), but her hemoglobin level continued to decline to 51 g/L one day after hormone therapy, so she received an intravenous infusion of washed red blood cells and underwent plasmapheresis, which eventually resolved the AIHA. Considering that the hemoglobin level was < 65 g/L and the irAE was grade 4, penpulimab was discontinued, and the symptoms of AIHA disappeared. From this event, we know that severe AIHA can occur after penpulimab use similar to other PD-1 antibodies. In this case, plasmapheresis showed a good therapeutic effect and should be used as a supplementary means when hormonal and immunosuppressive therapies cannot provide rapid symptom relief. In addition, we recommend regular direct antiglobulin testing, as well as haptoglobin, lactate dehydrogenase and other hemolysis-related laboratory tests, in patients prescribed penpulimab and similar drugs for the early diagnosis and treatment of AIHA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

Data availability

The datasets generated during and analysed during the current study are available from the corresponding author on reasonable request.

References

  1. Dhillon S (2021) Penpulimab: First approval. Drugs 81:2159–2166. https://doi.org/10.1007/s40265-021-01640-9

  2. Song Y, Zhou K, Jin C et al (2021) A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractoryclassic Hodgkin lymphoma (cHL) [abstract no. 7529]. J Clin Oncol 39:7529. https://doi.org/10.1200/JCO.2021.39.15_suppl.7529

  3. Chen X, Wang W, Zou Q et al (2020) A phase II study of the anti-programmed cell death-1 (pd-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (npc) who had progressed after two or more lines of chemotherapy. J Immunother Cancer 8:A481. https://doi.org/10.1136/jitc-2020-SITC2020.0804

    Article  Google Scholar 

  4. Han B, Chen J, Wang Z et al (2021) Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous nonsmall-cell lung cancer [abstract no. e21072]. J Clin Oncol 39(15):e21072. https://doi.org/10.1200/JCO.2021.39.15_suppl.e21072

  5. Singh R, Sheikh S, Pallagatti S et al (2015) Lymphocyte depleted Hodgkin's lymphoma presented with haemolytic anemia: A case report and literature review. J Maxillofac Oral Surg 14:317–322. https://doi.org/10.1007/s12663-013-0528-1

  6. Tardy MP, Gastaud L, Boscagli A, Peyrade F, Gallamini A, Thyss A (2017) Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report. Hematol Oncol 35:875–877. https://doi.org/10.1002/hon.2338.

  7. Paola G, Kristen M, Satish S, Brahmer JR, Naik RP (2021) Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review. Ann Hematol 101:1–10. https://doi.org/10.1007/s00277-021-04690-x

    Article  Google Scholar 

  8. Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245. https://doi.org/10.1038/clpt.1981.154

    Article  CAS  PubMed  Google Scholar 

  9. Chen Y, Pei Y, Luo J, Huang Z, Yu J, Meng X (2020) Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice. Front Immunol 11:1088. https://doi.org/10.3389/fimmu.2020.01088

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Barcellini W (2015) Immune Hemolysis: Diagnosis and Treatment Recommendations. Semin Hematol 52:304–312. https://doi.org/10.1053/j.seminhematol.2015.05.001

    Article  PubMed  Google Scholar 

  11. Jain NA, Zhao S, Wei L et al (2020) Association between RBC antigen allo-antibodies and immune-related adverse events during immune checkpoint inhibitor treatment for advanced cancers. Cancer Manag Res 12:11743–11749. https://doi.org/10.2147/CMAR.S264166

  12. Ogawa K, Ito J, Fujimoto D et al (2018) Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report. Invest New Drugs 36:509–512. https://doi.org/10.1007/s10637-018-0561-5

  13. Tanios GE, Doley PB, Munker R (2019) Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Eur J Haematol 102:157–162. https://doi.org/10.1111/ejh.13187

    Article  PubMed  Google Scholar 

Download references

Funding

The authors received no financial support for the research, authorship, and publication of this article.

Author information

Authors and Affiliations

Authors

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Yiming Tao Yongsheng li and Jie Han. The first draft of the manuscript was written by Yiming Tao and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Jie Han or Yongsheng Li.

Ethics declarations

Ethical approval

This is an observational study. The Qingdao Municipal Hospital Research Ethics Committee has confirmed that no ethical approval is required.v

Consent to participate

This paper has been published with the consent of patients and their families.

Consent to publish

The authors affirm that human research participants provided informed consent for publication of the images in Supplement Fig. 1A, B and C.

Competing interests

The authors have no relevant financial or non-financial interests to disclose.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 109 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tao, Y., Han, J. & Li, Y. Autoimmune hemolytic anemia in patients with relapsed Hodgkin’s lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1. Invest New Drugs 40, 854–857 (2022). https://doi.org/10.1007/s10637-022-01254-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-022-01254-2

Keywords

Navigation